Risk of 16 cancers across the full glycemic spectrum: a population-based cohort study using the UK Biobank. Issue 1 (27th August 2020)

• Record Type: Journal Article
• Authors: Rentsch, Christopher T; Farmer, Ruth E; Eastwood, Sophie V; Mathur, Rohini; Garfield, Victoria; Farmaki, Aliki-Eleni; Bhaskaran, Krishnan; Chaturvedi, Nish; Smeeth, Liam
• Is Part Of: BMJ open diabetes research and care. Volume 8:Issue 1(2020)
• Publication Date: 2020-08-27
• Subjects: glycated hemoglobin A -- hyperglycemia -- cohort studies -- epidemiology; Diabetes -- Periodicals; 616.462005
• DOI: 10.1136/bmjdrc-2020-001600
• Languages: English
• ISSNs: 2052-4897

Abstract

Abstract : Introduction: Diabetes is observed to increase cancer risk, leading to hypothesized direct effects of either hyperglycemia or medication. We investigated associations between glycosylated hemoglobin (HbA1c) across the whole glycemic spectrum and incidence of 16 cancers in a population sample with comprehensive adjustment for risk factors and medication. Research design and methods: Linked data from the UK Biobank and UK cancer registry for all individuals with baseline HbA1c and no history of cancer at enrollment were used. Incident cancer was based on International Classification of Diseases – 10th Edition diagnostic codes. Age-standardized incidence rates were estimated by HbA1c category. Associations between HbA1c, modeled as a restricted cubic spline, and cancer risk were estimated using Cox proportional hazards models. Results: Among 378 253 individuals with average follow-up of 7.1 years, 21 172 incident cancers occurred. While incidence for many of the 16 cancers was associated with hyperglycemia in crude analyses, these associations disappeared after multivariable adjustment, except for pancreatic cancer (HR 1.55, 95% CI 1.22 to 1.98 for 55 vs 35 mmol/mol), and a novel finding of an inverse association between HbA1c and premenopausal breast cancer (HR 1.27, 95% CI 1.00 to 1.60 for 25 vs 35 mmol/mol; HR 0.71, 95% CI 0.54 to 0.94 for 45 vs 35 mmol/mol), not observed for postmenopausal breast cancer. Adjustment for diabetes medications had no appreciable impact on HRs for cancer. Conclusions: Apart from pancreatic cancer, we did not demonstrate any independent positive association between HbA1c and cancer risk. These findings suggest that the potential for a cancer-inducing, direct effect of hyperglycemia may be misplaced.